Developer docs
API playgroundTry for free, no card

Search company profiles

Plusultra pharma

Full company profile

uuid003o6ha

Namestring
Plusultra pharma
Legal namestring
Plusultra pharma GmbH
Company typeenum
Private
Founded yearint
2020
Descriptiontext

Plusultra pharma GmbH is a privately held, Düsseldorf-based pharmaceutical company established in 2020 as the European operating subsidiary of Japan's Nobelpharma Co., Ltd. (founded 2003). The company develops and commercializes prescription pharmaceuticals for unmet medical needs, with an exclusive focus on orphan drugs and rare disease therapeutics — a niche it inherits from its parent group, which deliberately pursues "critical but neglected" products that larger pharmaceutical companies have not addressed. Its sole commercial product is Hyftor 2 mg/g Gel (Sirolimus), a topical gel formulation that received EMA marketing authorization on May 15, 2023, along with Orphan Drug Status, for the treatment of facial angiofibroma associated with tuberous sclerosis complex in adults and pediatric patients aged six and older.

The business model is conventional prescription pharmaceutical sales: Plusultra pharma holds the marketing authorization and captures revenue from product sales, while leveraging third-party partners for distribution and in-market promotion. In Germany, the home market, PHOENIX Pharma-Einkauf GmbH (Hanau) serves as the wholesale distributor to pharmacies and full-line wholesalers. Following successful price negotiations with the German statutory health insurance body GKV-SV in October 2024, Hyftor became fully reimbursable. In April and May 2025, Plusultra pharma announced a multi-country partnership with InfectoPharm Arzneimittel und Consilium GmbH covering exclusive marketing of Hyftor in France and Italy and a marketing collaboration in Germany, signaling a shift from single-market to multi-market European commercialization.

Plusultra pharma GmbH is a German limited liability company (GmbH) under Japanese parent ownership, with a sister entity, Plusultra pharma UK Ltd. (Oxford), established in 2020. The company does not publish revenue, headcount, or funding data; its financials are consolidated within Nobelpharma Group. Operating geographies at present include Germany, France, and Italy (the latter two via the InfectoPharm partnership), with the UK subsidiary not yet evidenced to have launched products. The company's competitive position rests on regulatory exclusivity from Orphan Drug Status, a niche specialization in neglected indications, and a lean asset-light commercial model built on partner distribution rather than owned sales infrastructure.

Short descriptiontext

Plusultra pharma GmbH is a Düsseldorf-based orphan drug subsidiary of Japan's Nobelpharma Group that markets Hyftor 2 mg/g Gel (Sirolimus), an EMA-approved prescription topical treatment for facial angiofibroma in tuberous sclerosis complex, distributed in Germany, France, and Italy.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersDüsseldorf, Germany
HQ citystring
Düsseldorf
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
orphan drug development, rare disease pharmaceuticals, specialty prescription drugs, tuberous sclerosis treatment, topical sirolimus gel
Industry1 code
PRIMARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Specialty Pharmaceuticals (Orphan Drugs)
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Product Sales
TypeOthers
Description

Revenue generated from sales of prescription-only pharmaceutical products, specifically Hyftor 2 mg/g Gel. Products are distributed through pharmacy networks via wholesale distribution partners. The company operates in the orphan drugs market segment for rare diseases.

plusultra-pharma.de:443
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Supply Chain, Technology or R&D, Operations, Marketing or Sales, Personnel
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Plusultra pharma GmbH is a research and development-based pharmaceutical company that develops and markets prescription pharmaceuticals for unmet medical needs, with a particular focus on orphan drugs for rare diseases. Its primary commercial product is Hyftor 2 mg/g Gel (Sirolimus), a topical prescription medication approved by the European Medicines Agency in May 2023 for the treatment of facial angiofibroma associated with tuberous sclerosis complex (TSC) in adults and pediatric patients aged six years and older. The company sells exclusively through pharmaceutical wholesale and channel partners that supply pharmacies and healthcare professionals across Germany, France, Italy, and the United Kingdom.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Plusultra pharma GmbH is a research and development-based pharmaceutical company that develops pharmaceuticals for unmet medical needs, including orphan drugs, off-label drugs, and treatments for intractable diseases. The company operates as a subsidiary of Nobelpharma Group (headquartered in Tokyo, Japan) with a focus on rare diseases. The primary product is Hyftor 2 mg/g Gel (Sirolimus), a prescription medication approved by EMA in May 2023 for treating facial angiofibroma associated with tuberous sclerosis complex. The company collaborates with distribution partners including PHOENIX Pharma-Einkauf GmbH for German market distribution and InfectoPharm for marketing in Germany, France, and Italy.

Product and service1 record
1Hyftor 2 mg/g Gel (Sirolimus)
CategorySpecialty prescription pharmaceutical (orphan drug)
Description

Prescription-only topical gel containing sirolimus indicated for the treatment of facial angiofibroma associated with tuberous sclerosis complex (TSC) in adults and pediatric patients aged six years and older. Distributed through pharmacies and pharmaceutical wholesalers in Germany and other European markets and reimbursed via GKV-SV in Germany.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-05-22
Description

Plusultra pharma and InfectoPharm announced partnership for marketing Hyftor 2 mg/g Gel in Germany. The collaboration leverages InfectoPharm's expertise in pharmaceutical marketing and distribution to expand reach of the orphan drug treatment for tuberous sclerosis complex patients.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-04-29
Description

Plusultra pharma and InfectoPharm signed binding term sheet for exclusive marketing of Hyftor 2 mg/g Gel in France and Italy. InfectoPharm will promote and distribute the product in these two countries, expanding the market for Hyftor 2 mg/g Gel across Europe.

3PHOENIX Pharma-Einkauf GmbH
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2023-11-01
Description

Distribution partner for Hyftor 2 mg/g Gel in Germany. Products distributed through pharmacies and fully stocked wholesalers. Located at Lippestrasse 9a, 63452 Hanau, Germany.

plusultra-pharma.de:443
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Global rare-disease biotech with multiple orphan drugs on the market. Comparable as a specialty pharma pure-play targeting small patient populations with high-unmet-need conditions, though operating at a much larger scale.

TypeBroad incumbent
Description

Major incumbent with Afinitor/Votubia (everolimus) approved for TSC-related manifestations including SEGA and renal angiomyolipoma. Direct competitor in the TSC treatment paradigm and a broad orphan/specialty pharma incumbent.

TypeBroad incumbent
Description

Established rare-disease franchise now part of AstraZeneca, offering multiple orphan drugs across EU. Comparable as a broader incumbent in the same specialty/rare-disease category, though with a much wider portfolio and deeper resources.

TypeDirect peer
Description

Commercial-stage rare-disease company developing and commercializing treatments for serious rare and ultra-rare genetic diseases. Comparable business model to Plusultra in targeting small orphan populations with regulatory exclusivity.

TypeDirect peer
Description

European-headquartered specialty pharmaceutical company focused exclusively on rare diseases. Directly comparable to Plusultra in mission, customer (rare-disease patients/prescribers), and orphan-drug commercialization model across EU markets.

6Orphan Europe (Recordati Group)
TypeDirect peer
Description

Recordati's dedicated rare-disease unit commercializing orphan drugs across Europe. Direct comparable to Plusultra in its European orphan-drug commercialization focus and small-patient-population go-to-market approach.

TypeDirect peer
Description

Specialty pharmaceutical company with a significant orphan and rare-disease franchise across oncology and neurology. Comparable as a specialty pharma operator commercializing niche, high-unmet-need therapeutics through targeted channels.

TypeDirect peer
Description

Specialty division of Recordati focused on rare and orphan diseases across Europe. Closely mirrors Plusultra's strategy of selling niche, high-unmet-need pharmaceuticals through established European distribution networks.

9HRA Pharma (Perrigo Company)
TypeDirect peer
Description

European specialty pharma with a dedicated rare-disease business (HRA Pharma Rare Diseases). Comparable as a focused orphan-drug marketer operating across EU regulatory and reimbursement environments.

TypeDirect peer
Description

European specialty pharmaceutical company focused on rare diseases, hospital-only medicines and specialty therapeutics. Comparable to Plusultra in its European orphan-drug focus and specialty distribution model.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Plusultra pharma

Specialty Pharmaceuticals (Orphan Drugs)plusultra-pharma.de

Plusultra pharma GmbH is a Düsseldorf-based orphan drug subsidiary of Japan's Nobelpharma Group that markets Hyftor 2 mg/g Gel (Sirolimus), an EMA-approved prescription topical treatment for facial angiofibroma in tuberous sclerosis complex, distributed in Germany, France, and Italy.

What Plusultra pharma does

Plusultra pharma GmbH is a privately held, Düsseldorf-based pharmaceutical company established in 2020 as the European operating subsidiary of Japan's Nobelpharma Co., Ltd. (founded 2003). The company develops and commercializes prescription pharmaceuticals for unmet medical needs, with an exclusive focus on orphan drugs and rare disease therapeutics — a niche it inherits from its parent group, which deliberately pursues "critical but neglected" products that larger pharmaceutical companies have not addressed. Its sole commercial product is Hyftor 2 mg/g Gel (Sirolimus), a topical gel formulation that received EMA marketing authorization on May 15, 2023, along with Orphan Drug Status, for the treatment of facial angiofibroma associated with tuberous sclerosis complex in adults and pediatric patients aged six and older.

The business model is conventional prescription pharmaceutical sales: Plusultra pharma holds the marketing authorization and captures revenue from product sales, while leveraging third-party partners for distribution and in-market promotion. In Germany, the home market, PHOENIX Pharma-Einkauf GmbH (Hanau) serves as the wholesale distributor to pharmacies and full-line wholesalers. Following successful price negotiations with the German statutory health insurance body GKV-SV in October 2024, Hyftor became fully reimbursable. In April and May 2025, Plusultra pharma announced a multi-country partnership with InfectoPharm Arzneimittel und Consilium GmbH covering exclusive marketing of Hyftor in France and Italy and a marketing collaboration in Germany, signaling a shift from single-market to multi-market European commercialization.

Plusultra pharma GmbH is a German limited liability company (GmbH) under Japanese parent ownership, with a sister entity, Plusultra pharma UK Ltd. (Oxford), established in 2020. The company does not publish revenue, headcount, or funding data; its financials are consolidated within Nobelpharma Group. Operating geographies at present include Germany, France, and Italy (the latter two via the InfectoPharm partnership), with the UK subsidiary not yet evidenced to have launched products. The company's competitive position rests on regulatory exclusivity from Orphan Drug Status, a niche specialization in neglected indications, and a lean asset-light commercial model built on partner distribution rather than owned sales infrastructure.

Plusultra pharma firmographics

Firmographics
Name
Plusultra pharma
Legal name
Plusultra pharma GmbH
Website
https://plusultra-pharma.de
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
1–10 employees
Short description
Plusultra pharma GmbH is a Düsseldorf-based orphan drug subsidiary of Japan's Nobelpharma Group that markets Hyftor 2 mg/g Gel (Sirolimus), an EMA-approved prescription topical treatment for facial angiofibroma in tuberous sclerosis complex, distributed in Germany, France, and Italy.
Ownership category
akta.pro rank

Plusultra pharma industry classification

Industry
Product category
Specialty Pharmaceuticals (Orphan Drugs)
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Orphan drug development
  • Rare disease pharmaceuticals
  • Specialty prescription drugs
  • Tuberous sclerosis treatment
  • Topical sirolimus gel

Where Plusultra pharma is headquartered

Location

Headquarters

HQ city
Düsseldorf
HQ country
Germany
HQ region
Europe

Offices2 records

Markets served

Plusultra pharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Technology or R&D, Operations, Marketing or Sales, Personnel

Revenue model

  1. Pharmaceutical Product Sales: Revenue generated from sales of prescription-only pharmaceutical products, specifically Hyftor 2 mg/g Gel. Products are distributed through pharmacy networks via wholesale distribution partners. The company operates in the orphan drugs market segment for rare diseases.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Plusultra pharma product offering

Product offering

Core offering

Plusultra pharma GmbH is a research and development-based pharmaceutical company that develops and markets prescription pharmaceuticals for unmet medical needs, with a particular focus on orphan drugs for rare diseases. Its primary commercial product is Hyftor 2 mg/g Gel (Sirolimus), a topical prescription medication approved by the European Medicines Agency in May 2023 for the treatment of facial angiofibroma associated with tuberous sclerosis complex (TSC) in adults and pediatric patients aged six years and older. The company sells exclusively through pharmaceutical wholesale and channel partners that supply pharmacies and healthcare professionals across Germany, France, Italy, and the United Kingdom.

Product overview

Plusultra pharma GmbH is a research and development-based pharmaceutical company that develops pharmaceuticals for unmet medical needs, including orphan drugs, off-label drugs, and treatments for intractable diseases. The company operates as a subsidiary of Nobelpharma Group (headquartered in Tokyo, Japan) with a focus on rare diseases. The primary product is Hyftor 2 mg/g Gel (Sirolimus), a prescription medication approved by EMA in May 2023 for treating facial angiofibroma associated with tuberous sclerosis complex. The company collaborates with distribution partners including PHOENIX Pharma-Einkauf GmbH for German market distribution and InfectoPharm for marketing in Germany, France, and Italy.

Differentiator

Problem solved

Functional benefit

Products and services

  • Hyftor 2 mg/g Gel (Sirolimus) Prescription-only topical gel containing sirolimus indicated for the treatment of facial angiofibroma associated with tuberous sclerosis complex (TSC) in adults and pediatric patients aged six years and older. Distributed through pharmacies and pharmaceutical wholesalers in Germany and other European markets and reimbursed via GKV-SV in Germany.

Companies that use Plusultra pharma

Customer profile

Segments1 record

Ideal customer profiles1 record

Plusultra pharma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Plusultra pharma partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • InfectoPharm Arzneimittel und Consilium GmbHcoreChannel Partner/ Reseller/ Distributor · 22 May 2025Plusultra pharma and InfectoPharm announced partnership for marketing Hyftor 2 mg/g Gel in Germany. The collaboration leverages InfectoPharm's expertise in pharmaceutical marketing and distribution to expand reach of the orphan drug treatment for tuberous sclerosis complex patients.
  • InfectoPharm Arzneimittel und Consilium GmbHcoreChannel Partner/ Reseller/ Distributor · 29 April 2025Plusultra pharma and InfectoPharm signed binding term sheet for exclusive marketing of Hyftor 2 mg/g Gel in France and Italy. InfectoPharm will promote and distribute the product in these two countries, expanding the market for Hyftor 2 mg/g Gel across Europe.
  • PHOENIX Pharma-Einkauf GmbHcoreChannel Partner/ Reseller/ Distributor · 1 November 2023Distribution partner for Hyftor 2 mg/g Gel in Germany. Products distributed through pharmacies and fully stocked wholesalers. Located at Lippestrasse 9a, 63452 Hanau, Germany.

Scale indicators2 records

Recent moves6 records

Expansion highlights4 records

Plusultra pharma competitors and assessment

Company assessment

Direct peers

  • BioMarin Pharmaceutical: Global rare-disease biotech with multiple orphan drugs on the market. Comparable as a specialty pharma pure-play targeting small patient populations with high-unmet-need conditions, though operating at a much larger scale.
  • Ultragenyx Pharmaceutical: Commercial-stage rare-disease company developing and commercializing treatments for serious rare and ultra-rare genetic diseases. Comparable business model to Plusultra in targeting small orphan populations with regulatory exclusivity.
  • Swedish Orphan Biovitrum (Sobi): European-headquartered specialty pharmaceutical company focused exclusively on rare diseases. Directly comparable to Plusultra in mission, customer (rare-disease patients/prescribers), and orphan-drug commercialization model across EU markets.
  • Orphan Europe (Recordati Group): Recordati's dedicated rare-disease unit commercializing orphan drugs across Europe. Direct comparable to Plusultra in its European orphan-drug commercialization focus and small-patient-population go-to-market approach.
  • Jazz Pharmaceuticals: Specialty pharmaceutical company with a significant orphan and rare-disease franchise across oncology and neurology. Comparable as a specialty pharma operator commercializing niche, high-unmet-need therapeutics through targeted channels.
  • Recordati Rare Diseases: Specialty division of Recordati focused on rare and orphan diseases across Europe. Closely mirrors Plusultra's strategy of selling niche, high-unmet-need pharmaceuticals through established European distribution networks.
  • HRA Pharma (Perrigo Company): European specialty pharma with a dedicated rare-disease business (HRA Pharma Rare Diseases). Comparable as a focused orphan-drug marketer operating across EU regulatory and reimbursement environments.
  • Advanz Pharma: European specialty pharmaceutical company focused on rare diseases, hospital-only medicines and specialty therapeutics. Comparable to Plusultra in its European orphan-drug focus and specialty distribution model.

Broad incumbents

  • Novartis: Major incumbent with Afinitor/Votubia (everolimus) approved for TSC-related manifestations including SEGA and renal angiomyolipoma. Direct competitor in the TSC treatment paradigm and a broad orphan/specialty pharma incumbent.
  • Alexion / AstraZeneca Rare Disease: Established rare-disease franchise now part of AstraZeneca, offering multiple orphan drugs across EU. Comparable as a broader incumbent in the same specialty/rare-disease category, though with a much wider portfolio and deeper resources.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

Plusultra pharma social profiles

Digital presence

Plusultra pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Plusultra pharma leadership team

Management profile

Number of profiles

Plusultra pharma funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Plusultra pharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Plusultra pharma

What does Plusultra pharma do?

Plusultra pharma GmbH is a research and development-based pharmaceutical company that develops and markets prescription pharmaceuticals for unmet medical needs, with a particular focus on orphan drugs for rare diseases. Its primary commercial product is Hyftor 2 mg/g Gel (Sirolimus), a topical prescription medication approved by the European Medicines Agency in May 2023 for the treatment of facial angiofibroma associated with tuberous sclerosis complex (TSC) in adults and pediatric patients aged six years and older. The company sells exclusively through pharmaceutical wholesale and channel partners that supply pharmacies and healthcare professionals across Germany, France, Italy, and the United Kingdom.

Is Plusultra pharma a public or private company?

Plusultra pharma is a private company. It is classified as corporate owned and is currently operating.

When was Plusultra pharma founded?

Plusultra pharma was founded in 2020. It employs 1 to 10 people.

Where is Plusultra pharma based?

Plusultra pharma is headquartered in Düsseldorf, Germany, in the Europe region.

How does Plusultra pharma make money?

One revenue line is on record: pharmaceutical Product Sales.

Who are Plusultra pharma's main competitors?

Direct peers on record are BioMarin Pharmaceutical, Ultragenyx Pharmaceutical, Swedish Orphan Biovitrum (Sobi), Orphan Europe (Recordati Group), Jazz Pharmaceuticals, Recordati Rare Diseases, HRA Pharma (Perrigo Company) and Advanz Pharma. Broad incumbents are Novartis and Alexion / AstraZeneca Rare Disease.

Does Plusultra pharma have an API?

No public API is recorded for Plusultra pharma.

What industry is Plusultra pharma in?

Plusultra pharma's product category is Specialty Pharmaceuticals (Orphan Drugs). Its primary akta.pro industry code is HLAIAAAB, Specialty Care Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales